AAPGV: מכפיל P/S Ascentage Pharma Group Ltd

The biotech sector possesses macro-resilience, as medical progress remains independent of GDP. High R&D costs and patents create an insurmountable barrier for competitors. Changes in the price-to-sales ratio confirm these theses, and 8.50 captures the current state of the parameter. Ascentage Pharma Group (AAPGV) focuses on targeted leukemia therapy in the US and China, developing drugs to combat chemotherapy resistance.

For Ascentage Pharma Group (AAPGV), whose potential in oncohematology is confirmed by international recognition, the P/S market multiple serves as an indicator for valuing future cash flows relative to current sales. This ratio is calculated as the relationship between market capitalization and annual revenue, allowing investors to determine whether the business is overvalued or to identify undervalued assets within the context of the company's therapeutic prospects.